NEW YORK (GenomeWeb) – Arrowhead Research announced this week that it has acquired the RNAi drug assets of Novartis, giving the firm access to a portfolio of technologies, intellectual property, and drug candidates developed by the pharmaceutical giant over the past 10 years.

The deal also marks the second time Arrowhead has snapped up the RNAi assets of a big pharma that spent considerable time and money on transforming the gene-silencing technology into a therapeutic modality, only to later drop out amid corporate reorganizations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.